

FAX RECEIVED

DEC 31 2001

GROUP 1600

Patent Docket P1219P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Stewart, T. et al. Serial No.: 09/522,342 Filed: March 9, 2000 For: FIBROBLAST GROWTH FACTOR -19 (FGF-19) NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE FOR THE TREATMENT OF OBESITY	Group Art Unit: 1647 Examiner: Saoud, Christine J.
 CERTIFICATE OF MAILING I hereby certify that the correspondence containing my Response to Restriction Requirements (Under 35 C.F.R. § 1.121) is being transmitted electronically via facsimile transmission to the Commissioner of Patents, Washington, D.C. December 28, 2001 <i>[Signature]</i> Aida Graham	

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 C.F.R. §1.121

Assistant Commissioner of Patents
 Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated November 29, 2001, please consider the election and remarks.

Election:

Applicants received a Communication from the Examiner dated November 29, 2001 which contained a requirement for restriction in connection with the application captioned above. More specifically, the Examiner has required a restriction under 35 U.S.C. § 121 of one of the following inventions:

Group I: Claims 1-22, drawn to polynucleotides, vectors, host cells and methods of making a polypeptide, classified in class 435, subclass 69.4, for example;